-
admin
Posts
Embrace the Holiday Magic in The Bahamas
Island Focus: Grand Bahama Island Nassau, Bahamas, Dec. 02, 2024 (GLOBE NEWSWIRE) — As the chill of winter descends upon much of the northern hemisphere,...
Interparfums, Inc. To Develop Off-White Brand in Fragrance and Beauty Category
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) — Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that its 72% owned French subsidiary,...
Preferred Hotels & Resorts Unveils Highly Anticipated New Luxury Hotel Openings
From urban boutiques to remote hideaways, discover the independent hotel brand’s 2024 – 2025 hotel debuts NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) — Preferred...
K. Hovnanian® Homes Launches Groundbreaking New Website
MATAWAN, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) — K. Hovnanian® Homes celebrates the launch of their new and improved website, www.khov.com, launched on November 13,...
Riyadh Art Celebrates Riyadh Train Launch with Artworks Illuminating the Urban and Cultural Landscape
RIYADH, Saudi Arabia, Dec. 02, 2024 (GLOBE NEWSWIRE) — Riyadh Art, the world’s largest public art program, is an unparalleled cultural infrastructure initiative that reimagines...
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing...
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy NEW YORK, Dec. 02, 2024...
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing...
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on...
